GlobalData on MSN
AstraZeneca’s novel COPD drug secures double win in Phase III
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...
Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.
The rate of new chronic obstructive pulmonary disease (COPD) cases decreased from 2001 to 2020, although the prevalence of COPD has increased.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results